The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Instant ramen maker Nissin Foods is leveraging the buzz around GLP-1s to launch in the US a trio of decadent tasting frozen ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

We view a Medifast revitalization as hinging on a steep coach network inflection. Read why we think MED stock becomes a core ...

Weight loss drugs like Ozempic have gained a lot of popularity However these medications are not without side effects One ...